Renal tubular dysfunction in patients with rheumatoid arthritis starting with low dose methotrexate;Ocena czynności kanalika proksymalnego u chorych na reumatoidalne zapalenie stawów, rozpoczynaja̧cych leczenie metotreksatem

Polskie Archiwum Medycyny Wewnetrznej

Volumn 110, Issue 2, 2003, Pages 855-862

  Wiland, Piotr ^a   Wiela Hojeńska, Anna ^b   Świerkot, Jerzy ^b   Hurkacz, Magdalena ^b   Orzechowska Juzwenko, Krystyna ^b   Szechiński, Jacek ^b  

^a Szpital Kolejowego   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Methotrexate; N acetyl beta D glucosaminidase; NAG; Renal tubular dysfunction; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; N ACETYL BETA GLUCOSAMINIDASE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CREATININE CLEARANCE; ENZYME ACTIVITY; ENZYMURIA; FEMALE; HUMAN; INFLAMMATION; KIDNEY TUBULE DISORDER; KIDNEY TUBULE FUNCTION; LOW DRUG DOSE; MALE; RHEUMATOID ARTHRITIS; URINARY EXCRETION; URINE LEVEL;

EID: 0041377727     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Deray G., Khayat D., Cacoub P. i wsp.: The effects of diltiazem on methotrexate-induced nephrotoxicity. Eur. J. Clin. Pharmacol., 1989, 37, 337.
2. Olah V.A., Bekesi A., Toth A., Kovacs I., Balla G.: Urinary N-acetylo-beta-D-glucosaminidase activity in leukaemic children during high-dose methotrexate therapy. Haematologia, 1995, 26, 151.
3. Diener U., Knoll E., Langer B., Rautenstrauch H., Ratge D., Wisser H.: Urinary excretion of NAG and alaninoaminopeptodase in patients receiving amikacin or cisplatinum. Clin. Chim. Acta, 1981, 112, 149.
4. Whiting P.H., Nicholls A.J., Catto G.R.D., Edward N., Engeset J.: Patterns of N-acetylo-beta-D-glucosaminidase excretion after renal transplantation. Clin. Chim. Acta 1980, 108, 1.
5. Wiela-Hojeńska A., Orzechowska-Juzwenko K.: N-acetylo-beta-D-glukozaminidaza i jej znaczenie kliniczne. Pol. Arch. Med. Wewn., 1999, 101, 359.
6. Wiland P., Szechiński J.: N-acetyl-beta-D-glucosaminidase enzymuria as an indicator in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs. Arch. Immunol. Ther. Exp., 1994, 42, 331.
7. Price R.G., Dance N., Richards B., Cattell W.R.: The excretion of N-acetyl-beta-D-glucosaminidase and beta-galactosidase following surgery to the kidney. Clin. Chim. Acta, 1970, 27, 67.
8. Wiland P., Świerkot J., Szechiński J.: N-acetyl-β-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment. Br. J. Rheumatol., 1997, 36, 59.
9. Chatterjee S., Velicer L.L., Sweeley C.C.: Glycosphingolipid glycosyl hydrolases and glycosidases of synchronized human KB cells. J. Biol. Chem., 1975, 250, 4972.
10. Zwierz K., Gindzieński A., Głowacka D., Porowski T.: The degradation of glycoconjugates in the human gastric mucous membrane. Acta Med. Acad. Sci. Hung., 1981, 38, 145.
11. Kremer J.M., Hamilton R.A., Petrillo G.F.: Pharmacokinetics of methotrexate with and without non-steroidal antiinflammatory drug administration. Arthritis Rheum., 1992, 35, S142 (suppl.).
12. Schnabel A., Gross W.L.: Low-dose methotrexate in rheumatic diseases-efficacy side effects and risk factors for side effects. Semin. Arthritis Rheum., 1994, 23, 310.
13. Bannwarth B., Pehourcq F., Schaeverbeke T., Dehais J.: Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet., 1996, 30, 194.
14. Bressolle F, Bologna C., Kinowski J.M., Sany J., Combe B.: Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann. Rheum. Dis., 1998, 57, 110.
15. Kennedy C., Baker H.: Renal function in methotrexate treated psoriatics. Br. J. Dermatol., 1976, 94, 702.
16. Wolfe F., Cathey M.A.: The effect of age on methotrexate efficiacy and toxicity. J. Rheumatol., 1991, 18, 973.
17. Zachariae H., Hansen H.E., Sogaard H. i wsp.: Kidney biopsies in methotrexate-treated psoriatics. Dermatologica 1990, 181, 273.
18. Van Jaarsveld C.H.M., Jahangier Z.N., Jacobs J.W.G. i wsp.: Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatology 2000, 39, 1374.
19. Scott D.L., Whelton A., Smolen J.S., Weaver, Emery P., Strand V.: Renal effects of leflunomide compared with other agents used to treat rheumatoid arthritis (RA) XIV EULAR Congress Abstract Book. Ann. Rheum. Dis., 1999, S212.
20. Kremer J.M., Petrillo G.F., Hamilton R.A.: Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J. Rheumatol., 1995, 22, 38.
21. Seideman P., Müller-Suur R., Ekman E.: Renal effects of low dose methotrexate in rheumatoid arthritis J. Rheumatol., 1993, 20, 1126.
22. Seideman P, Müller-Suur R.: Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Ann. Rheum. Dis., 1993, 52, 613.
23. Rheumatoid Arthritis Clinical Trial Archive Group.: The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J. Rheumatol., 1995, 22, 218.
24. El-Badawi M.G., Abdalla M.A., Bahakim H.M., Fadel R.A.: Nephrotoxicity of low-dose methotrexate in guinea pigs: an ultrastructural study. Nephron 1996, 73, 462.
25. Goren M.P., Wright R.K., Horowitz M.E., Crom W.R., Meyer W.H.: Urinary N-acetyl-beta-D-glucosaminidase and serum creatinine concentrations predict impaired excretion of methotrexate. J. Clin. Oncol., 1987, 5, 804.